- Home
- ZH vs CKPT Comparison
ZH vs CKPT Comparison
Compare ZH & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- CKPT
- Stock Information
- Founded
- ZH 2011
- CKPT 2014
- Country
- ZH China
- CKPT United States
- Employees
- ZH N/A
- CKPT N/A
- Industry
- ZH Business Services
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- CKPT Health Care
- Exchange
- ZH Nasdaq
- CKPT Nasdaq
- Market Cap
- ZH 353.6M
- CKPT 361.1M
- IPO Year
- ZH 2021
- CKPT 2017
- Fundamental
- Price
- ZH $4.01
- CKPT N/A
- Analyst Decision
- ZH Strong Buy
- CKPT Buy
- Analyst Count
- ZH 1
- CKPT 3
- Target Price
- ZH $4.70
- CKPT $4.33
- AVG Volume (30 Days)
- ZH 172.9K
- CKPT 2.1M
- Earning Date
- ZH 05-27-2025
- CKPT 05-13-2025
- Dividend Yield
- ZH N/A
- CKPT N/A
- EPS Growth
- ZH N/A
- CKPT N/A
- EPS
- ZH N/A
- CKPT N/A
- Revenue
- ZH $464,095,225.00
- CKPT $41,000.00
- Revenue This Year
- ZH N/A
- CKPT $102,182.93
- Revenue Next Year
- ZH $7.46
- CKPT $351.71
- P/E Ratio
- ZH N/A
- CKPT N/A
- Revenue Growth
- ZH N/A
- CKPT N/A
- 52 Week Low
- ZH $2.55
- CKPT $1.80
- 52 Week High
- ZH $6.32
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- ZH 53.05
- CKPT 3.56
- Support Level
- ZH $3.74
- CKPT $4.14
- Resistance Level
- ZH $4.22
- CKPT $4.28
- Average True Range (ATR)
- ZH 0.15
- CKPT 0.02
- MACD
- ZH 0.01
- CKPT -0.52
- Stochastic Oscillator
- ZH 56.61
- CKPT 0.00
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.